CMTM7 (CKLF-like MARVEL transmembrane domain-containing 7) is a member of the chemokine-like factor (CKLF) superfamily, characterized by a conserved MARVEL domain involved in membrane apposition and trafficking. It is widely expressed in human tissues, including immune cells, and plays roles in regulating receptor stability, immune responses, and tumor suppression. CMTM7 is localized to the plasma membrane and endosomes, where it interacts with transmembrane proteins such as EGFR and HER2. modulating their ubiquitination, internalization, and downstream signaling pathways (e.g., PI3K/AKT, MAPK). Its loss or downregulation has been linked to cancer progression, metastasis, and poor prognosis in malignancies like glioblastoma, breast, and gastric cancers.
Antibodies targeting CMTM7 are essential tools for studying its expression, localization, and molecular interactions. These antibodies (often rabbit or mouse monoclonal/polyclonal) are validated for applications including Western blotting, immunohistochemistry, immunofluorescence, and flow cytometry. Researchers use them to explore CMTM7's tumor-suppressive mechanisms, such as its role in destabilizing oncogenic receptors or enhancing immune cell activity (e.g., T-cell chemotaxis). Commercial CMTM7 antibodies are typically accompanied by knockdown/knockout validation to ensure specificity. Ongoing studies focus on its potential as a therapeutic target or biomarker in cancer and immune-related diseases.